---
title: "ABCL.US (ABCL.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ABCL.US/news.md"
symbol: "ABCL.US"
name: "ABCL.US"
parent: "https://longbridge.com/en/quote/ABCL.US.md"
datetime: "2026-05-20T04:38:58.769Z"
locales:
  - [en](https://longbridge.com/en/quote/ABCL.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ABCL.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ABCL.US/news.md)
---

# ABCL.US (ABCL.US) — Related News

### [Is AbCellera (ABCL) Quietly Rewriting Its Business Model With ABCL635’s Phase II Menopause Bet?](https://longbridge.com/en/news/286842930.md)
*2026-05-19T02:14:39.000Z*
> AbCellera Biologics reported Q1 2026 results with revenue at $8.32 million and a net loss of $43.17 million. The company

### [12 Health Care Stocks Moving In Monday's After-Market Session](https://longbridge.com/en/news/286000465.md)
*2026-05-11T21:05:54.000Z*
> In Monday's after-market session, PACS Group shares surged 15.4% to $36.8 following its Q1 earnings report, with a marke

### [](https://longbridge.com/en/news/285997804.md)
*2026-05-11T20:56:52.000Z*
> AbCellera Biologics shares are trading higher after the company reported better-than-expected Q1 financial results.

### [Abcellera Biologics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.315 M](https://longbridge.com/en/news/285990870.md)
*2026-05-11T20:21:50.000Z*
### [Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara](https://longbridge.com/en/news/285178972.md)
*2026-05-05T09:14:15.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [AbCellera Biologics Pivots to In-House Pipeline, Teases Q3 Phase II Data for ABCL635 Hot Flashes](https://longbridge.com/en/news/284004893.md)
*2026-04-24T12:43:17.000Z*
> AbCellera Biologics (NASDAQ:ABCL) is transitioning from a partnership-driven model to focus on its own clinical pipeline

### [AbCellera Biologics (ABCL) Is Up 6.8% After Announcing First Human Data Timeline For ABCL635](https://longbridge.com/en/news/283564378.md)
*2026-04-21T21:57:42.000Z*
> AbCellera Biologics (ABCL) shares rose 6.8% following the announcement of interim Phase 1 data for its antibody ABCL635,

### [Top European Undervalued Small Caps With Insider Action In April 2026](https://longbridge.com/en/news/283095336.md)
*2026-04-17T05:45:33.000Z*
> As European markets rise, investors are focusing on undervalued small-cap stocks with insider buying. Notable companies